BioMarin Pharmaceutical I... (BMRN)
BioMarin Pharmaceutical Inc. (BMRN) Stock Price, Analysis & Data
| Bid | 67.01 |
| Market Cap | 13.6B |
| Revenue (ttm) | 3.41B |
| Net Income (ttm) | 72.97M |
| Beta | 0.23 |
| EPS (ttm) | 0.37 |
| PE Ratio (ttm) | 189.84 |
| Forward PE | 10.6 |
| P/B (ttm) | 2.15 |
| P/S (ttm) | 3.99 |
| Earnings Date | Oct 26, 2026 |
| Ask | 73.12 |
| Volume | 2,801,650 |
| Avg. Volume (20D) | 2,174,535 |
| Open | 68.71 |
| Previous Close | 69.55 |
| Day's Range | 68.43 - 70.98 |
| 52-Week Range | 49.26 - 70.98 |
| Analyst | Buy |
| Price Target | 86 (22.44%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About BMRN
BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, the Middle East, the Asia Pacific, and internationally. The company's products include VIMIZIM, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; VOXZOGO, a onc...
Financial Performance
In 2025, BioMarin Pharmaceutical's revenue was 3.22B, an increase of 12.87% compared to the previous year's 2.85B. Earnings were 348.9M, a decrease of -18.26%.
Financial StatementsAnalyst Forecast
According to 25 analyst ratings, the average rating for BMRN stock is "Buy". The 12-month stock price forecast is 86, which is upside of 22.44% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
